Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
1.680
+0.100 (6.33%)
At close: Jun 26, 2026, 4:00 PM EDT
1.640
-0.040 (-2.38%)
After-hours: Jun 26, 2026, 6:58 PM EDT
Acrivon Therapeutics Employees
As of December 31, 2025, Acrivon Therapeutics had 76 total employees, including 74 full-time and 2 part-time employees. The number of employees decreased by 2 or -2.56% compared to the previous year.
Employees
76
Change (1Y)
-2
Growth (1Y)
-2.56%
Revenue / Employee
n/a
Profits / Employee
-$1,016,671
Market Cap
71.91M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 76 | -2 | -2.56% |
| Dec 31, 2024 | 78 | 17 | 27.87% |
| Dec 31, 2023 | 61 | 17 | 38.64% |
| Dec 31, 2022 | 44 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Gossamer Bio | 162 |
| XBiotech | 87 |
| Seres Therapeutics | 66 |
| Pliant Therapeutics | 49 |
| BeyondSpring | 44 |
| Elicio Therapeutics | 33 |
| eXoZymes | 32 |
| Gain Therapeutics | 21 |
ACRV News
- 13 days ago - Acrivon Therapeutics assumed with an Outperform at Oppenheimer - TheFly
- 4 weeks ago - Acrivon Therapeutics Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - Transcripts
- 5 weeks ago - Acrivon Therapeutics Proxy statement: Proxy filing - Filings
- 5 weeks ago - Acrivon Therapeutics to Present at TD Cowen's 7th Annual Oncology Innovation Summit - GlobeNewsWire
- 6 weeks ago - Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Acrivon Therapeutics reports Q1 EPS (49c), consensus (52c) - TheFly
- 6 weeks ago - Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts - GlobeNewsWire
- 6 weeks ago - Acrivon Therapeutics Earnings release: Q1 2026 - Filings